Eva Catalá
YOU?
Author Swipe
View article: Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy. Open
The advantages of the protocol include reducing economic costs, saving storage space, simplifying the manufacturing process, and facilitating shipping logistics. In conclusion, we present a validated, simple, and cost-effective cell enrich…
View article: Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo
Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo Open
Background: Median age at diagnosis of diffuse large B cell lymphoma (DLBCL) patients is 66 years; 40% of patients are diagnosed at an age greater than 70 years. CAR-T cell therapy is approved for the treatment of relapsed/refractory DLBCL…
View article: P1401: IDENTIFICATION OF BIOMARKERS AND RISK FACTORS FOR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN CD19-DIRECTED CAR T-CELL THERAPY: A RETROSPECTIVE MACHINE LEARNING-BASED ANALYSIS.
P1401: IDENTIFICATION OF BIOMARKERS AND RISK FACTORS FOR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN CD19-DIRECTED CAR T-CELL THERAPY: A RETROSPECTIVE MACHINE LEARNING-BASED ANALYSIS. Open
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown great potential as a treatment for patients with relapsed or refractory diffuse l…
View article: Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma Open
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate…
View article: Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies Open
Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunog…
View article: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain Open
INTRODUCTION: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic raises many questions about the management of patients with significant comorbidities. Hematologic patients are usually fragile due to an important imm…